The crisis of no new antibiotics--what is the way forward?
暂无分享,去创建一个
[1] N. Thomson,et al. Complete Sequence and Molecular Epidemiology of IncK Epidemic Plasmid Encoding blaCTX-M-14 , 2011, Emerging infectious diseases.
[2] P. De Wals,et al. Pneumonia After Implementation of the Pneumococcal Conjugate Vaccine Program in the Province of Quebec, Canada , 2008, The Pediatric infectious disease journal.
[3] Christophe Corre,et al. Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in Streptomyces ambofaciens , 2011, Proceedings of the National Academy of Sciences.
[4] A. Clatworthy,et al. Targeting virulence: a new paradigm for antimicrobial therapy , 2007, Nature Chemical Biology.
[5] S. Levy,et al. Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.
[6] V. Fischetti,et al. Bacteriophage lysins as effective antibacterials. , 2008, Current opinion in microbiology.
[7] J. Coast,et al. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness , 2002, Journal of health services research & policy.
[8] L. Greene,et al. Impact of antibiotic resistance , 2011, BMJ : British Medical Journal.
[9] Christopher M Thomas,et al. A Natural Plasmid Uniquely Encodes Two Biosynthetic Pathways Creating a Potent Anti-MRSA Antibiotic , 2011, PloS one.
[10] Brad Spellberg,et al. Combating antimicrobial resistance: policy recommendations to save lives. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] G Kahlmeter,et al. Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[12] Elias Mossialos,et al. Stoking the antibiotic pipeline , 2010, BMJ : British Medical Journal.
[13] C. Baron. Antivirulence drugs to target bacterial secretion systems. , 2010, Current opinion in microbiology.
[14] N. Woodford,et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study , 2010, The Lancet. Infectious diseases.
[15] S. Projan,et al. Why is big Pharma getting out of antibacterial drug discovery? , 2003, Current opinion in microbiology.
[16] J. Frère,et al. Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement. , 2008, The Lancet. Infectious diseases.
[17] Bala Hota,et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] S. Levy,et al. Novel anti-infection agents: small-molecule inhibitors of bacterial transcription factors. , 2007, Bioorganic & medicinal chemistry letters.
[19] C. Nathan,et al. The profit problem in antibiotic R&D , 2005, Nature Reviews Drug Discovery.
[20] D. Pompliano,et al. Nat. Rev. Drug Disc. , 2007 .
[21] H. Goossens,et al. Society's failure to protect a precious resource: antibiotics , 2011, The Lancet.
[22] W. Schaffner,et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. , 2010, The Journal of infectious diseases.
[23] M. M. Rahman,et al. Medicinal plant extracts with efflux inhibitory activity against Gram-negative bacteria. , 2011, International journal of antimicrobial agents.
[24] I. Okeke,et al. Diagnostics as essential tools for containing antibacterial resistance. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[25] P Huovinen,et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.
[26] A. White. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control. , 2011, The Journal of antimicrobial chemotherapy.
[27] M. M. Rahman,et al. Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria. , 2010, The Journal of antimicrobial chemotherapy.
[28] D. Barlocco. Muraglitazar (Bristol-Myers Squibb/Merck). , 2005, Current opinion in investigational drugs.
[29] J. Bartlett,et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] Regulatory opportunities to encourage technology solutions to antibacterial drug resistance. , 2011, The Journal of antimicrobial chemotherapy.
[31] K. Bostian,et al. Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use. , 2006, Biochemical pharmacology.
[32] D. Livermore. Discovery research: the scientific challenge of finding new antibiotics. , 2011, The Journal of antimicrobial chemotherapy.
[33] O. Cars,et al. The global need for effective antibiotics-moving towards concerted action. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[34] Qijing Zhang,et al. Sensitization of Campylobacter jejuni to fluoroquinolone and macrolide antibiotics by antisense inhibition of the CmeABC multidrug efflux transporter. , 2009, The Journal of antimicrobial chemotherapy.
[35] J. Mecsas,et al. Small Molecule Inhibitors of LcrF, a Yersinia pseudotuberculosis Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model , 2010, Infection and Immunity.
[36] V. Ricci,et al. Exploiting the Role of TolC in Pathogenicity: Identification of a Bacteriophage for Eradication of Salmonella Serovars from Poultry , 2010, Applied and Environmental Microbiology.
[37] D. Pompliano,et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.
[38] D. Hung,et al. Productive steps toward an antimicrobial targeting virulence. , 2009, Current opinion in microbiology.
[39] H. D. de Melker,et al. Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands , 2010, Emerging infectious diseases.
[40] N. Chan-Tompkins. Multidrug-Resistant Gram-Negative Infections , 2011, Critical care nursing quarterly.
[41] J. Hughes,et al. Preserving the lifesaving power of antimicrobial agents. , 2011, JAMA.
[42] L. Rice. Rapid diagnostics and appropriate antibiotic use. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] Bonnie L Bassler,et al. A strategy for antagonizing quorum sensing. , 2011, Molecular cell.
[44] L. Berti,et al. Geraniol Restores Antibiotic Activities against Multidrug-Resistant Isolates from Gram-Negative Species , 2009, Antimicrobial Agents and Chemotherapy.
[45] R. Wise. The urgent need for new antibacterial agents. , 2011, The Journal of antimicrobial chemotherapy.